2026年3月8日閲覧. ^ Cerus Internationalsは380万株以上を販売し,株が180ドルで閉鎖されて8.6%から11.6%に減少した. In March 2026, Cerus insiders sold over 380,000 shares, reducing stakes by 8.6% to 11.6%, as stock closed at $1.80.

2026年3月12日閲覧. ^ Cerus Internationalsは,コオ・ヴィエク・ジャヤラマンが1株当たり平均1.66ドル(約36万円)の額で,合計で380万株以上を販売した. On March 12, 2026, Cerus Corporation insiders sold a combined total of over 380,000 shares, including 165,200 by COO Vivek Jayaraman, at an average price of $1.66 per share, totaling approximately $630,000. 売却により,株価は8.6%減って11.6%となり,3月15日に株価は1.80ドルで終了した. The sales reduced their stakes by 8.6% to 11.6%, with the company’s stock closing at $1.80 on March 15. Cerusは3月2日にQ4の利益を発表し,株当たり0.01ドルの損失と推定額を上回る64,580万ドルの収益で期待に応じた. Cerus reported Q4 earnings on March 2, meeting expectations with a $0.01 loss per share and $64.58 million in revenue, above estimates. このバイオテクノロジー会社は INTERCEPT 血液システムを通じて 血液の安全性に焦点を当てています 市場総額は3億4500万ドルで 分析者の評価は 混在しており 総論は"減少"という 推奨値です The biotech firm, focused on blood safety via its INTERCEPT Blood System, has a market cap of $345.91 million and a mixed analyst rating, with a consensus "Reduce" recommendation.